Drug Trial Radar · NCT05841394
A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding
Last checked: Nov 19, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
449
Actual
Start
Jul 16, 2021
Primary completion
Apr 28, 2022
Study completion Apr 28, 2022
Sponsor
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry
- Sponsor type
- Industry
- First posted
- May 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of the study drug (Ilaprazole Sodium for Injection) for potential effect on preventing stress ulcer bleeding in vulnerable population by comparing the radio of upper gastrointestinal bleeding when they are administered Ilaprazole Sodium for Injection and Esomeprazole Sodium for Injection respectively.
Conditions
- Stress Ulcer Bleeding
Interventions
Esomeprazole 40mgDrug
40 mg i.v. twice daily (q12h)
Ilaprazole SodiumDrug
10 mg i.v. once daily, 20 mg i.v. in the first day.
Placebo 1Drug
Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
Placebo 2Drug
Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Preventing clinically significant gastrointestinal bleedingTime frame: Day 1 to Day 3
- Preventing clinically significant gastrointestinal bleedingTime frame: Day 1 and Day 2
- Preventing clinically significant gastrointestinal bleedingTime frame: Day 3
- Preventing clinically significant gastrointestinal bleedingTime frame: Day 1 to Day 3
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Jiaotong University Affiliate Ruijin Hospital
Shanghai, Shanghai Municipality, China
The First Affiliated Hopspital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.